Key Highlights
- Total Revenue was USD 242.72 million against USD 156.72 million a year earlier.
- Loss per share was USD 0.66 against an estimate of a USD 1.23 loss.
- HIBSAGO FDA approval in October triggered a USD 30 million milestone payment.
- TRYNGOLZA 2026 revenue guidance was lowered to approximately USD 50 million.
Ionis Pharmaceuticals (NASDAQ:IONS) reported third quarter 2026 total revenue of USD 242.72 million, compared with USD 156.72 million in the third quarter of 2025. The loss per share was USD 0.66, against an estimate of a USD 1.23 loss and a USD 0.80 loss a year earlier.
Net loss was USD 109.97 million, compared with USD 128.61 million in the prior-year quarter. The loss from operations was USD 130.70 million, against USD 160.18 million. Management said the company continued to evolve as a commercial stage biotechnology company through the first three quarters of 2026.
Revenue and Operating Expenses
Total Research and Development revenue was USD 106.52 million, compared with USD 41.12 million a year earlier. For the nine months, total revenue was USD 756.76 million, against USD 740.38 million in the same period of 2025.
Selling, general and administrative expenses were USD 154.22 million, against USD 96.81 million. Total operating expenses were USD 373.42 million, compared with USD 316.90 million. Nine-month net loss was USD 317.15 million, or USD 1.92 per share, against USD 151.99 million, or USD 0.95 per share.
Commercial Portfolio and Guidance
The company's chief executive officer, Brett Monia, said the Ionis-owned commercial portfolio now includes TRYNGOLZA for familial chylomicronemia syndrome and for severe hypertriglyceridemia, DAWNZERA for hereditary angioedema, and ZANVASTRO, its first independent launch in neurology. Management also noted the approval of HIBSAGO for chronic hepatitis B virus in the United States, and described the TRYNGOLZA launch for severe hypertriglyceridemia as its first launch in a large patient population.
Management said it is encouraged by the fundamentals underlying the TRYNGOLZA launch, including strong physician enthusiasm, and is refining its launch tactics to translate that enthusiasm into action. The filing also recounts a 2017 collaboration with Novartis to develop and commercialize pelacarsen.
Management lowered its 2026 full year TRYNGOLZA revenue guidance to approximately USD 50 million to reflect a more gradual launch ramp than it had anticipated. It said it continues to target its full year 2026 total revenue, operating loss and cash guidance, and that DAWNZERA momentum supports confidence in its 2026 product sales guidance.
HIBSAGO Milestone and Liquidity
The filing states that in October 2026 the company achieved a USD 30 million milestone payment when the FDA approved HIBSAGO for the treatment of chronic hepatitis B infection. A further payment of up to USD 35 million is triggered if HIBSAGO is approved in China, and the company has received more than USD 135 million in upfront and other payments related to the program.
Cash and cash equivalents were USD 296.30 million and short-term investments were USD 1.59 billion at September 30, 2026. The filing says the company believes its cash, cash equivalents and short-term investments, along with plans for future cash, are sufficient to fund its planned operations and obligations.
Ionis Pharmaceuticals Q3 2026 Earnings: Key Takeaways
Ionis Pharmaceuticals reported third quarter 2026 total revenue of USD 242.72 million and a loss per share of USD 0.66. Net loss was USD 109.97 million, and management lowered its 2026 TRYNGOLZA revenue guidance to approximately USD 50 million.






Please wait processing your request...